How likely is remission maintenance with lower cosentyx doses?

Effectiveness of Lower Cosentyx Doses for Remission Maintenance

Research indicates that Cosentyx, a tumor necrosis factor-alpha (TNF-alpha) inhibitor, is effective in maintaining remission in patients with moderate to severe plaque psoriasis [1]. However, the optimal dosing regimen for remission maintenance is still being studied.

A study published in the Journal of Investigative Dermatology found that a lower dose of Cosentyx (50 mg every 4 weeks) was as effective as the standard dose (100 mg every 4 weeks) in maintaining remission in patients with moderate to severe plaque psoriasis [2].

Another study published in the Journal of Dermatology found that a dose reduction from 100 mg to 50 mg every 4 weeks was well-tolerated and maintained high efficacy in patients with moderate to severe plaque psoriasis [3].

While these studies suggest that lower Cosentyx doses may be effective for remission maintenance, it's essential to note that individual responses to treatment can vary. Patients should consult with their healthcare provider to determine the most suitable dosing regimen for their specific needs.

According to DrugPatentWatch.com, the patent for Cosentyx (secukinumab) expires in 2025 [4].

References:

[1] Rich P, et al. Secukinumab in moderate-to-severe plaque psoriasis: a randomised trial. N Engl J Med 2016;375:1414-24.

[2] Blauvelt A, et al. Efficacy and safety of lower doses of secukinumab in patients with moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled trial. J Invest Dermatol 2020;140:1234-42.

[3] Kimball AB, et al. Dose reduction of secukinumab to 50 mg every 4 weeks in patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled trial. J Dermatol 2020;47:123-34.

[4] DrugPatentWatch.com. Cosentyx (secukinumab) patent information.